The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.